The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.
This article was originally published by HCPLive®. It has been lightly edited.
The FDA issued marketing denial orders (MDOs) for 6 Vuse Alto brand-associated flavored e-cigarette products after determining the products did not meet standards for public health benefits and risks.1
The MDOs, issued to RJ Reynolds Vapor Company, target the largest sold brand of e-cigarettes in the United States and ensures the 6 products cannot be introduced into interstate commerce nor marketed for sale.
“The Center for Tobacco Products continues to make meaningful progress in reviewing the unprecedented amount of premarket tobacco product applications that have been received,” Director of the FDA’s Center for Tobacco Products Brian King, PhD, MPH, said in a statement. “We’re committed to completing review of these applications as soon as possible while ensuring that they undergo a rigorous scientific review in accordance with the law.”
The FDA determined the company’s premarket tobacco product applications (PMTAs) for the impacted products—3 menthol-flavored and 3 mixed berry-flavored products, with each flavor being offered in 3 nicotine strengths—provided insufficient evidence toward the appropriate regulation of such products relative to the public health impact they would have.
“Specifically, evidence submitted by the applicant did not demonstrate that the menthol- and mixed berry-flavored products provided an added benefit for adults who smoke cigarettes—in terms of complete switching or significant smoking reduction—relative to that of tobacco-flavored products that is sufficient to outweigh the known risks to youth,” the FDA statement read.
The agency additionally cited data from the National Youth Tobacco Survey showing that cartridge-based Vuse e-cigarettes have been the second most commonly reported vape brand used by US youth since 2021. The MDOs come 2 weeks following the FDA’s issuance of civil money penalty fines against 22 retailers due to their illegal sale of an e-cigarette brand known to strongly appeal to US youth.2
The company may be able to submit new applications for regulated use in the US for these impacted products. To date, just 23 tobacco-flavored e-cigarette products and devices have been authorized by the FDA.1
“We review each application on its own merits, and it’s the responsibility of the applicant to provide sufficient science to support the product they’re seeking to market,” Director of the FDA’s Center for Tobacco Product’s Office of Science Matthew Farrelly, PhD, said in a statement. “If an application contained sufficient scientific evidence to meet the necessary public health standard, including a non-tobacco-flavored product, we’d authorize the product. But such evidence was lacking in this case.”
References
Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD
May 2nd 2024Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.
Read More
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More